Cheelcare Announces Third Quarter 2026 Financial Results

Cheelcare Inc. (TSXV:CHER) reported its third-quarter financial results for the period ending January 31, 2026, showcasing a record revenue of CAD 549,857, a 16% increase from CAD 473,795 in the same quarter of the previous year. This performance is attributed to the growing adoption of its mobility solutions, particularly the Companion power-assist device, which recently received Pricing, Data Analysis, and Coding (PDAC) verification for reimbursement eligibility through U.S. Medicare and Medicaid programs. This milestone is expected to significantly enhance market penetration across Cheelcare's U.S. dealer network, which has expanded to over 500 locations globally, including the top three dealer networks in North America. The company also achieved a commercial milestone by surpassing 2,000 cumulative units sold, reflecting increasing brand recognition and market acceptance.

Financially, Cheelcare reported a gross profit of CAD 208,630, representing a gross margin of 44.3%, a substantial improvement from 31.2% in the prior year. However, the company recorded a net loss of CAD 509,824, or CAD 0.02 per share, compared to a loss of CAD 310,083, or CAD 0.04 per share in Q3 2025. This increase in losses is primarily attributed to planned investments in production scale-up, regulatory readiness, and costs associated with being a public company. As of January 31, 2026, Cheelcare had cash and cash equivalents of CAD 83,642 and working capital of CAD 355,047. Following the quarter-end, the company secured a CAD 1 million unsecured promissory note financing on February 18, 2026, aimed at bolstering working capital and supporting inventory and manufacturing activities.

The operational highlights indicate a strategic focus on scaling production capabilities, which is crucial as Cheelcare prepares for anticipated demand increases. The company is also advancing its regulatory initiatives, particularly for its Curio robotic complex-rehab power wheelchair, which is currently under review with Ontario's Assistive Devices Program and undergoing the U.S. FDA 510(k) pre-market notification process. The completion of cybersecurity testing for Curio is a significant step towards the submission of the 510(k) application. Cheelcare's CEO, Eugene Cherny, emphasized the importance of these milestones for expanding market access and supporting adoption as the company transitions into the next phase of commercialization.

In terms of valuation, Cheelcare's market capitalization stands at CAD 34 million, placing it within the micro-cap tier. To assess its valuation relative to peers, it is essential to identify comparable companies in the same sector and market cap tier. However, the specific peer group for Cheelcare is limited due to its unique focus on advanced mobility solutions, which does not have a broad array of direct competitors within the same market cap range. Nevertheless, companies such as Invacare Corporation (NYSE:IVC) and Sunrise Medical Holdings, Inc. (OTC:SNZUY) can be considered as indirect competitors, although they may not fit perfectly within the micro-cap tier. The absence of direct peers limits the ability to conduct a comprehensive valuation comparison based on metrics such as EV/revenue or EV/EBITDA.

Cheelcare's financial position indicates a need for careful management of its cash resources, particularly given the net loss reported and the ongoing investments in scaling operations. The recent financing of CAD 1 million provides a temporary buffer, but with cash reserves of only CAD 83,642, the company faces a funding runway that could be precarious if additional capital is not secured. The company’s burn rate, while not explicitly stated, can be inferred from the net loss and cash position, suggesting a need for further financing within the next few months to sustain operations and support growth initiatives.

The appointment of Natasha Tsai as Chief Financial Officer, effective April 7, 2026, marks a strategic move as the company transitions from foundational buildout to scaling operations. Tsai's background in financial operations and experience with growth-stage companies may provide the necessary expertise to navigate the challenges ahead. However, the resignation of the previous CFO, Arnab De, could introduce a degree of uncertainty during this transition period.

One specific risk highlighted by the announcement is the reliance on regulatory approvals for the Curio device, which remains under review by both the Ontario Assistive Devices Program and the U.S. FDA. Delays in these processes could hinder Cheelcare's ability to capitalize on market opportunities and could impact revenue growth projections. Furthermore, the company’s dependence on Medicare and Medicaid reimbursement for the Companion device introduces additional regulatory risks that could affect sales performance.

Looking ahead, the next measurable catalyst for Cheelcare is the anticipated updates on the regulatory and reimbursement initiatives for the Curio device, expected in the second or third quarter of calendar 2026. These updates will be critical in determining the company’s ability to expand its market access and drive adoption of its products.

In conclusion, Cheelcare's third-quarter results reflect a significant step forward in its operational and financial trajectory, marked by record revenues and strategic milestones in regulatory approvals. However, the ongoing net losses and limited cash reserves raise concerns about funding sufficiency and operational sustainability. The announcement is classified as moderate in materiality, given the positive revenue growth and regulatory achievements, but tempered by the risks associated with funding and regulatory dependencies. The company's ability to navigate these challenges will be crucial in determining its future valuation and market positioning.

Key insights

• ●Cheelcare achieved record revenue of CAD 549,857 in Q3 2026.
• ●The company faces a net loss of CAD 509,824 amid scaling efforts.
• ●Regulatory approvals for Curio are critical for future growth.

Disagree with this article?